Six readers
| reader | found | score |
|---|---|---|
| genetics Open Targets | no genetic evidence; overall 0.10 from other evidence | 0.00 |
| cell type Human Protein Atlas | expressed broadly, no clear home in brain cells | 0.40 |
| chemistry Open Targets | reachable by antibody | 0.45 |
| trials ClinicalTrials.gov | 14 Parkinson's trials, 1 stopped | 0.94 |
| literature PubMed | 91 Parkinson's papers of 38,104 | 0.41 |
| pathways Reactome | 37 pathways; mostly vesicle traffic | 1.00 |
No case: the score is under the bar. Receipt 2523
Sealed predictions
- EGF in dopamine neurons, braak+0.13 (p 0.741) → +0.60 (p 0.090)receipt 2530
Swarm cases
receipt 2530: EGF in dopamine neurons, braak
- power
- full sample +0.34 (p 0.161, n 18), 95% CI -0.15 to +0.70. the interval is wide: not enough donors to tell.
- confounder
- adjusted for sex: +0.33 (p 0.188, n 18). does not hold up.
- composition
- dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: +0.40 (p 0.097, n 18). could be the mix.
- skeptic
- leave-one-out range +0.26 to +0.50, sign flips 0; without severely affected donors +0.34 (p 0.161, n 18). fragile.
- cell type
- no other cell group does better.
- axis
- no measure beats "tracks Braak Lewy-body stage" for EGF in dopamine neurons.
case closed: nothing better to follow up.
Receipts
loading the receipts